X4 Pharmaceuticals Overview
- Founded
-
2014
- Status
-
Public
- Employees
-
74
- Stock Symbol
-
XFOR
- Investments
-
1
- Share Price
-
$0.90
- (As of Tuesday Closing)
X4 Pharmaceuticals General Information
Description
X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Its product candidate, X4P-001, has completed a Phase 2 trial in patients with a rare genetic PI called Warts. The company is also developing X4P-002, a CXCR4 antagonist that has properties that could enable penetration of the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers, including glioblastoma multiforme.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 61 North Beacon Street
- 4th Floor
- Boston, MA 02134
- United States
+1 (857) 000-0000
X4 Pharmaceuticals Timeline
X4 Pharmaceuticals Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.90 | $0.89 | $0.65 - $2.41 | $109M | 122M | 807K | -$1.52 |
X4 Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 79,146 | 79,146 | 27,863 | 46,881 |
| Revenue | 0 | 0 | 0 | 3,000 |
| EBITDA | (89,552) | (89,552) | (84,548) | (59,217) |
| Net Income | (93,867) | (93,867) | (88,696) | (62,131) |
| Total Assets | 155,586 | 155,586 | 117,176 | 122,871 |
| Total Debt | 38,420 | 38,420 | 39,785 | 38,448 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
X4 Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
X4 Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
X4 Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system functio
Biotechnology
Boston, MA
74
As of 2023
00000
000000000
00000
000000
aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volup
000000000000000
West Conshohocken, PA
00
As of 0000
000.00
000000 - 000
000.00
000000
dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident
0000 000000000
Cambridge, MA
000
00.00
0000-00-00
00000000000
000
Add Comparison
X4 Pharmaceuticals Competitors (55)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Corporation | West Conshohocken, PA | 00 | 000.00 | 000000 - 000 | 000.00 |
| 0000000 | Venture Capital-Backed | Cambridge, MA | 000 | 00000000000 | 000 | |
| 00000000 000000000 | Formerly VC-backed | Bedford, MA | 00 | 00000 | 000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Watertown, MA | 00 | 00000 | 000000000 | 00000 |
| 000000000 00000000 | Venture Capital-Backed | Hennigsdorf, Germany | 00 | 000.00 | 0000000000 0 | 000.00 |
X4 Pharmaceuticals Patents
X4 Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220017487-A1 | Deuterated compounds and uses thereof | Pending | 16-Jul-2020 | 000000000 | 0 |
| CA-3171250-A1 | Methods for treating neutropenia | Pending | 10-Mar-2020 | 00000000000 | |
| EP-4117662-A1 | Methods for treating neutropenia | Pending | 10-Mar-2020 | 00000000000 | |
| US-20230014231-A1 | Methods for treating neutropenia | Pending | 10-Mar-2020 | 00000000000 | |
| CA-3144650-A1 | Cxcr4 inhibitors and uses thereof | Pending | 26-Jun-2019 | A61P35/00 |
X4 Pharmaceuticals Executive Team (22)
X4 Pharmaceuticals Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alison Lawton | X4 Pharmaceuticals | Board Member | 000 0000 |
| David McGirr | Arsanis | Board Member | 000 0000 |
| Francoise de Craecker | X4 Pharmaceuticals | Board Member | 000 0000 |
| Gary Bridger Ph.D | X4 Pharmaceuticals | Board Member | 000 0000 |
| Isaac Blech | Self | Board Member | 000 0000 |
X4 Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
X4 Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
X4 Pharmaceuticals Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 | 13-Mar-2019 | 0000000000 | 000.00 | Biotechnology | 00000 000 |
X4 Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated October, 22, 2020
33.72 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 947
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 427
Rank
00.0
Percentile
